Efocipegtrutide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Efocipegtrutide is an experimental shot that works on three signals, GLP-1, GIP and glucagon. It is being made mainly for fatty liver disease.
Evidence grade for Efocipegtrutide: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 2 completed trials, 215 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 215
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 215 people given it
1 effects reported, 1 unwanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Efocipegtrutide, also called HM15211, is an experimental shot from Hanmi. It works on three signals, GLP-1, GIP and glucagon, like retatrutide. It is being made mainly for fatty liver disease. It is not approved.
What people take it for
- Treating fatty liver disease.
- Weight loss.
What studies in people showed
There are no published results in people yet. A mid-stage study in 215 people with fatty liver disease, confirmed by a liver sample, finished collecting data in June 2026. Nothing has been reported. A paper on the study plan says it looked good in animals and was tolerable in the first studies in people.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- No results or side effect data have been published yet.
Where these come from: Everything here is from the study record and the study plan on this page. There are no user reports.
My bottom line
No results, no verdict. Anything sold under this name is a guess in a vial.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Efocipegtrutide?
Efocipegtrutide is an experimental shot that works on three signals, GLP-1, GIP and glucagon. It is being made mainly for fatty liver disease.
Efocipegtrutide, also called HM15211, is an experimental long-acting drug from Hanmi Pharmaceutical. It works on three signals: GLP-1, GIP and glucagon. That is the same idea as retatrutide. It is being made mainly for MASH, a fatty liver disease that inflames the liver. It is further behind than retatrutide. A mid-stage study in 215 people, whose liver disease was confirmed with a liver sample, finished collecting its main data in June 2026. The results are not published yet.
How does Efocipegtrutide work?
It turns on the GLP-1, GIP and glucagon signals. Together they cut appetite, help release insulin, raise the energy the body burns and act on the liver.
The evidence, in charts
Fig. 1a · how many people
215people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| ClinicalTrials.gov 2026 | 215 | 100% |
The whole total is one study of 215. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2023 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Not disclosed
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Efocipegtrutide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2023A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed NASH: study design and rationale
There is no result in this paper. It describes how a trial should be run in patients whose fatty liver disease was confirmed by taking a sample of the liver. It notes the drug looked promising in animals and was tolerable in the first human studies. A plan for a trial is not evidence from one.
Design paper; notes efficacy signals in preclinical NASH models and Phase 1 studies with manageable toxicity.
- Study in people2026Study to evaluate efficacy, safety and tolerability of HM15211 (efocipegtrutide) in subjects with biopsy-confirmed NASH
This is a trial record rather than a published result. A middle stage study in 215 people with biopsy confirmed fatty liver disease finished collecting its main data in June 2026. Hanmi is the sponsor. Nothing has been reported, so nobody outside the company yet knows what it found.
Phase 2, 215 participants, sponsored by Hanmi; status completed with primary completion June 26, 2026.
Where to buy Efocipegtrutide
No seller we track lists Efocipegtrutide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Efocipegtrutide been tested in people?
Yes. 215 people given it across 2 completed trials cited here, 0 of which found nothing. Efocipegtrutide is an experimental shot that works on three signals, GLP-1, GIP and glucagon. It is being made mainly for fatty liver disease.
What is the Efocipegtrutide dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 215 people given it
Is Efocipegtrutide FDA-approved?
Investigational. A mid-stage study in MASH, a serious fatty liver disease, finished in mid-2026. Results are not out yet
How does efocipegtrutide compare to retatrutide?
Both work on GLP-1, GIP and glucagon. Retatrutide is further along and aimed at obesity. Efocipegtrutide has been aimed more at fatty liver disease.